Patients with facial acne scar. facial acne scar, acne scar,
Conditions
Interventions
Patients were treated by using a 755-nanometer picosecond laser equipped with a diffractive lens on facial atrophic acne scars. Treatment will be administered to both sides of the face. A total of si
Experimental Device
755 nm Picosecond Laser with Diffractive Lens Array for Treatment of Atrophic Acne Scars
Sponsors
Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand
Eligibility
Sex/Gender
All
Age
20 Years to 50 Years
Inclusion criteria
Inclusion criteria: 1. Aged between 20 and 50 years. 2. Patients with atrophic acne scars on the facial area. 3. Patients who willingly consent to participate in the study. 4. Patients with moderate to severe severity of acne scars based on the Global Acne Scar Grading System.
Exclusion criteria
Exclusion criteria: 1. Patients who are pregnant or breastfeeding. 2. Patients with a history of collagen-related disorders, such as Cushing syndrome or Ehlers-Danlos syndrome. 3. Patients with facial dermatitis, wounds, or active skin infections. 4. Patients who have cancer, are currently undergoing cancer treatment, or have skin cancer in the treatment area. 5. Patients with a history of immunodeficiency, including those with HIV infection or AIDS. 6. Patients with a history of allergy to local anesthetics. 7. Patients with a history of abnormal photosensitivity. 8. Patients who have received facial treatment with dermal fillers, botulinum toxin, collagen biostimulators, platelet-rich plasma (PRP), or thread lifting within 6 months prior to study. 9. Patients who have undergone laser treatment for acne scars on the face within 6 months prior to study. 10. Patients with a history of hypertrophic scars or dermatitis in the treatment area. 11. Patients who have used vitamin A or its derivatives within 6 months prior to study. 12. Patients with a history of psychiatric disorders. 13. Patients with any condition that may pose a safety risk if participating in the study. 14. Patients who do not consent to having photographs taken for treatment evaluation purposes.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| skin texture and depression volume baseline, 1 month after 4th treatment, 1 month after 6th treatment, 1, 3 and 6 months after complete the treatment. Antera 3D | — |
Secondary
| Measure | Time frame |
|---|---|
| Melanin and erythema index baseline, 1 month after 4th treatment, 1 month after 6th treatment, 1, 3 and 6 months after complete the treatment. mexameter,Physician improvement scale baseline, 1 month after 4th treatment, 1 month after 6th treatment, 1, 3 and 6 months after complete the treatment. Quartile scale,Patient improvement scale baseline, 1 month after 4th treatment, 1 month after 6th treatment, 1, 3 and 6 months after complete the treatment. Quartile scale | — |
Countries
Thailand
Contacts
Public ContactWoraphong Manuskiatti
Faculty of Medicine Siriraj Hospital, Mahidol University
Outcome results
None listed